Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of Acute Lymphoblastic Leukemia
CONCLUSION: EcA variants demonstrated better pharmacological properties compared to WT that makes them good candidates for further development.PMID:38412663 | DOI:10.1016/j.tranon.2024.101909 (Source: Translational Oncology)
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Soumika Sengupta Mainak Biswas Khushboo A Gandhi Saurabh Kumar Gupta Poonam B Gera Vikram Gota Avinash Sonawane Source Type: research
XIAP overexpressing inflammatory breast cancer patients have high infiltration of immunosuppressive subsets and increased TNFR1 signaling targetable with Birinapant
CONCLUSION: Using immunophenotyping and gene expression analysis in patient biospecimens along with in silico modeling and a preclinical model with a pan-IAP antagonist, this study revealed an interplay between increased TAMs, TNF-α signaling, and XIAP activation during (immune) stress in IBC. These data demonstrate the potential of IAP antagonists as immunomodulators for improving IBC therapeutic regimens.PMID:38412664 | DOI:10.1016/j.tranon.2024.101907 (Source: Translational Oncology)
Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Christophe Van Berckelaer Steven Van Laere Seayoung Lee Michael A Morse Joseph Geradts Luc Dirix Mark Kockx Fran çois Bertucci Peter Van Dam Gayathri R Devi Source Type: research
Comprehensive genomic and clinical analyses identify APOBEC mutational signatures as a brain metastasis risk factor in lung adenocarcinoma patients
CONCLUSION: APOBEC mutational signatures related to upregulated TGFβ and EMT, could serve as an independent risk factor for BM and BM-free survival in metastatic lung adenocarcinoma patients. Further investigations are warranted to tailor personalized treatments to improve the susceptible patient's outcomes.PMID:38402722 | DOI:10.1016/j.tranon.2024.101921 (Source: Translational Oncology)
Source: Translational Oncology - February 25, 2024 Category: Cancer & Oncology Authors: Qiang Li Meng Jiang Shiqiang Hong Jing Yang Xiaoying Wu Jiaohui Pang Yedan Chen Xiaotian Zhao Xiao Ding Source Type: research
Comprehensive genomic and clinical analyses identify APOBEC mutational signatures as a brain metastasis risk factor in lung adenocarcinoma patients
CONCLUSION: APOBEC mutational signatures related to upregulated TGFβ and EMT, could serve as an independent risk factor for BM and BM-free survival in metastatic lung adenocarcinoma patients. Further investigations are warranted to tailor personalized treatments to improve the susceptible patient's outcomes.PMID:38402722 | DOI:10.1016/j.tranon.2024.101921 (Source: Translational Oncology)
Source: Translational Oncology - February 25, 2024 Category: Cancer & Oncology Authors: Qiang Li Meng Jiang Shiqiang Hong Jing Yang Xiaoying Wu Jiaohui Pang Yedan Chen Xiaotian Zhao Xiao Ding Source Type: research
CT-guided high dose rate brachytherapy can induce multiple systemic proteins of proliferation and angiogenesis predicting outcome in HCC
CONCLUSION: Increased plasma levels of EGF and Angiopoietin-1 after HDR-BT for HCC are associated with poor response and may therefore function as predictive biomarkers of outcome.PMID:38401507 | DOI:10.1016/j.tranon.2024.101919 (Source: Translational Oncology)
Source: Translational Oncology - February 24, 2024 Category: Cancer & Oncology Authors: Lukas Salvermoser Shraga Nahum Goldberg Marianna Alunni-Fabbroni Philipp Maximilian Kazmierczak Moritz Nikolaus Gr öper Jan Niklas Sch äfer Elif Öcal Tanja Burkard Stefanie Corradini Najib Ben Khaled Agnese Petrera Moritz Wildgruber Jens Ricke Matthias Source Type: research
CT-guided high dose rate brachytherapy can induce multiple systemic proteins of proliferation and angiogenesis predicting outcome in HCC
CONCLUSION: Increased plasma levels of EGF and Angiopoietin-1 after HDR-BT for HCC are associated with poor response and may therefore function as predictive biomarkers of outcome.PMID:38401507 | DOI:10.1016/j.tranon.2024.101919 (Source: Translational Oncology)
Source: Translational Oncology - February 24, 2024 Category: Cancer & Oncology Authors: Lukas Salvermoser Shraga Nahum Goldberg Marianna Alunni-Fabbroni Philipp Maximilian Kazmierczak Moritz Nikolaus Gr öper Jan Niklas Sch äfer Elif Öcal Tanja Burkard Stefanie Corradini Najib Ben Khaled Agnese Petrera Moritz Wildgruber Jens Ricke Matthias Source Type: research
Apigenin enhances sorafenib anti-tumour efficacy in hepatocellular carcinoma
CONCLUSIONS: In conclusion, Apigenin could enhance the therapeutic efficacy of Sorafenib against liver cancer and may be a promising therapeutic approach for treating HCC. However, further research is imperative to gain more in-depth mechanistic insights.PMID:38394865 | DOI:10.1016/j.tranon.2024.101920 (Source: Translational Oncology)
Source: Translational Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Deepti Singh Mohammad Afsar Khan Dhruv Mishra Aditya Goel Mairaj Ahmed Ansari Kafil Akhtar Hifzur R Siddique Source Type: research
Genetic testing for hereditary cancer syndromes in Tunisian patients: Impact on health system
CONCLUSION: Our study calls for comprehensive genetic education and the implementation of genetic screening in Tunisia and other African countries health systems, to reduce the burden of hereditary diseases and improve cancer outcomes in resource-stratified settings.PMID:38387387 | DOI:10.1016/j.tranon.2024.101912 (Source: Translational Oncology)
Source: Translational Oncology - February 22, 2024 Category: Cancer & Oncology Authors: Nouha Jandoubi Maroua Boujemaa Najah Mighri Nesrine Mejri Sonia Ben Nasr Hanen Bouaziz Yosra Berrazega Haifa Rachdi Nouha Daoud Aref Zribi Jihene Ayari Houda El Benna Soumaya Labidi Abderazzek Haddaoui Ridha Mrad Slim Ben Ahmed Hamouda Boussen Sonia Abdel Source Type: research
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma
CONCLUSION: Integrative machine learning analysis was performed to construct a novel IRS in cholangiocarcinoma. This IRS acted as an indicator for predicting the prognosis and immunotherapy benefits of cholangiocarcinoma patients.PMID:38387388 | DOI:10.1016/j.tranon.2024.101905 (Source: Translational Oncology)
Source: Translational Oncology - February 22, 2024 Category: Cancer & Oncology Authors: Xu Chen Bo Sun Yu Chen Yili Xiao Yinghui Song Sulai Liu Chuang Peng Source Type: research
Genetic testing for hereditary cancer syndromes in Tunisian patients: Impact on health system
CONCLUSION: Our study calls for comprehensive genetic education and the implementation of genetic screening in Tunisia and other African countries health systems, to reduce the burden of hereditary diseases and improve cancer outcomes in resource-stratified settings.PMID:38387387 | DOI:10.1016/j.tranon.2024.101912 (Source: Translational Oncology)
Source: Translational Oncology - February 22, 2024 Category: Cancer & Oncology Authors: Nouha Jandoubi Maroua Boujemaa Najah Mighri Nesrine Mejri Sonia Ben Nasr Hanen Bouaziz Yosra Berrazega Haifa Rachdi Nouha Daoud Aref Zribi Jihene Ayari Houda El Benna Soumaya Labidi Abderazzek Haddaoui Ridha Mrad Slim Ben Ahmed Hamouda Boussen Sonia Abdel Source Type: research
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in cholangiocarcinoma
CONCLUSION: Integrative machine learning analysis was performed to construct a novel IRS in cholangiocarcinoma. This IRS acted as an indicator for predicting the prognosis and immunotherapy benefits of cholangiocarcinoma patients.PMID:38387388 | DOI:10.1016/j.tranon.2024.101905 (Source: Translational Oncology)
Source: Translational Oncology - February 22, 2024 Category: Cancer & Oncology Authors: Xu Chen Bo Sun Yu Chen Yili Xiao Yinghui Song Sulai Liu Chuang Peng Source Type: research
Multi-omics analysis-based macrophage differentiation-associated papillary thyroid cancer patient classifier
CONCLUSION: Based on the co-expression network analysis results, we identified three subtypes of IMPTCC: Immune-Suppressive Macrophage differentiation-associated Papillary Thyroid Carcinoma Classification (ISMPTCC), Immune-Neutral Macrophage differentiation-associated Papillary Thyroid Carcinoma Classification (INMPTCC), and Immune-Activated Macrophage differentiation-associated Papillary Thyroid Carcinoma Classification (IAMPTCC). Each subtype exhibits distinct metabolic, immune, and regulatory characteristics corresponding to different states of macrophage differentiation.PMID:38382228 | DOI:10.1016/j.tranon.2024.101889 ...
Source: Translational Oncology - February 21, 2024 Category: Cancer & Oncology Authors: Hanlin Sun Zhengyan Chang Hongqiang Li Yifeng Tang Yihao Liu Lixue Qiao Guicheng Feng Runzhi Huang Dongyan Han De-Tao Yin Source Type: research
Multi-omics analysis-based macrophage differentiation-associated papillary thyroid cancer patient classifier
CONCLUSION: Based on the co-expression network analysis results, we identified three subtypes of IMPTCC: Immune-Suppressive Macrophage differentiation-associated Papillary Thyroid Carcinoma Classification (ISMPTCC), Immune-Neutral Macrophage differentiation-associated Papillary Thyroid Carcinoma Classification (INMPTCC), and Immune-Activated Macrophage differentiation-associated Papillary Thyroid Carcinoma Classification (IAMPTCC). Each subtype exhibits distinct metabolic, immune, and regulatory characteristics corresponding to different states of macrophage differentiation.PMID:38382228 | DOI:10.1016/j.tranon.2024.101889 ...
Source: Translational Oncology - February 21, 2024 Category: Cancer & Oncology Authors: Hanlin Sun Zhengyan Chang Hongqiang Li Yifeng Tang Yihao Liu Lixue Qiao Guicheng Feng Runzhi Huang Dongyan Han De-Tao Yin Source Type: research
Polyene phosphatidylcholine enhances the therapeutic response of oxaliplatin in gastric cancer through Nrf2/HMOX1 mediated ferroptosis
In conclusion, our study reveals the synergistic antitumour potential of PPC and OXA while protecting patients against hepatic injury. This suggests a promising combined treatment approach for patients with advanced gastric cancer.PMID:38377934 | DOI:10.1016/j.tranon.2024.101911 (Source: Translational Oncology)
Source: Translational Oncology - February 20, 2024 Category: Cancer & Oncology Authors: Peijie Lei Lianjing Cao Hongjun Zhang Jialei Fu Xiaojuan Wei Fei Zhou Jingjing Cheng Jie Ming Haijun Lu Tao Jiang Source Type: research
Revealing underlying regulatory mechanisms of LINC00313 in Osimertinib-resistant LUAD cells by ceRNA network analysis
CONCLUSIONS: Our results suggest that the LINC00313/miR-218-5p/COL1A1 axis potentially contributes to osimertinib resistance through the PI3K/Akt signaling pathway, providing novel insights into the molecular mechanisms underlying acquired osimertinib resistance in LUAD. Additionally, our study may aid in the identification of potential therapeutic targets for overcoming resistance to osimertinib.PMID:38377935 | DOI:10.1016/j.tranon.2024.101895 (Source: Translational Oncology)
Source: Translational Oncology - February 20, 2024 Category: Cancer & Oncology Authors: Dandan Ding Chenguang Xu Jufeng Zhang Ying Zhang Lipeng Xue Jingjing Song Zhiming Luo Xiaoyu Hong Jian Wang Weicheng Liang Xingyang Xue Source Type: research
